USFDA issues EIR for Cohance Lifesciences Telangana facility

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-05-26 10:00 GMT   |   Update On 2025-05-26 10:00 GMT

Hyderabad: Cohance Lifesciences, formerly Suven Pharmaceuticals Ltd, has announced that the Company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API Unit-IV, located at Plot No. A-21, Road No. 10, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, Telangana, India.

The inspection was conducted from March 3, 2025 to March 7, 2025. The inspection was classified as Voluntary Action Indicated (VAI) and indicates the formal closure of the inspection process by the USFDA.

Voluntary action indicated (VAI) means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

Read also: Suven Pharma rebranded as Cohance Lifesciences

Cohance Lifesciences is a technology-driven CDMO, providing integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators. The company has over 100 active projects and a pipeline of late-stage molecules.

Read also: Advent International to purchase significant stake in Suven Pharma, plans merger with Cohance Lifesciences


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News